Evidence map›Paper›PMID 40898647›Full record

ArticleNeuropathology and applied neurobiology2025

Neuropathological Characterisation of McLeod Syndrome With a Proposed New Grading System.

Anna Maria Reuss, Klavs Renerts, Tibor Hortobágyi, Felix Geser, Johannes Haybaeck, Adrian Danek, Peter Fuhr, Bjarne Udd, Adam Zeman, Reichard R Ross and 2 more

Erratum issuedAbstract read
In one paragraph

Article in Neuropathology and applied neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Anna Maria ReussInstitute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-1096-3030
Klavs RenertsDepartment of Neurology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Tibor HortobágyiInstitute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Felix GeserInstitute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Johannes HaybaeckInstitute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Adrian DanekDepartment of Neurology, Ludwig-Maximilian-University (LMU), University Hospital Munich, Munich, Germany.
Peter FuhrDepts. of Neurology and of Clinical Research, University Hospital Basel, Basel, Switzerland.
Bjarne UddNeuromuscular Center, Tampere University Hospital, Tampere, Finland.
Adam ZemanDepartment of Clinical Neurosciences, University of Edinburgh, Edinburgh, UK.
Reichard R RossDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Elisabeth J RushingInstitute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Hans H JungDepartment of Neurology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsX-linked McLeod neuroacanthocytosis syndrome (MLS) is a rare neurodegenerative disorder characterised by the presence of red blood cell acanthocytosis and a chorea syndrome. Analogous to Huntington's disease (HD), MLS displays cognitive and behavioural symptoms besides the progressive movement disorder. This study aimed to describe the neuropathology of MLS in the largest case series to date.

methodsClinical data were collected, and neuropathological assessments were performed on eight male MLS patients originating from Finland, New Zealand, Switzerland, Scotland and the United States.

resultsMacroscopic data were available from six patients, with five showing atrophy of the basal ganglia, which was more pronounced in the caudate nucleus and to a lesser extent in the putamen and pallidum. Histology revealed neuronal loss and accompanying gliosis in the basal ganglia of all patients. The extent of these alterations varied widely, with a decreasing gradient of severity from the caudate nucleus to the putamen and the pallidum, mirroring the macroscopic findings. In addition, we detected intraneuronal vacuoles in the striatum in half of the patients.

conclusionsMLS neuropathology is characterised macroscopically by atrophy and microscopically by neuronal loss and gliosis of the basal ganglia, with a decreasing gradient of severity from the caudate nucleus, the putamen to the pallidum. Analogous to the grading system for HD, we propose a neuropathological grading system for MLS based on the current observations in the largest MLS cohort examined to date. Standardised criteria are crucial for neuropathological assessment of this extremely rare disease.

Indexed as

Basal GangliaBrainGenetic Diseases, X-LinkedNeuroacanthocytosisAdultAgedAtrophyGliosisHumansMaleMiddle AgedNeuronsgliosishistologymovement disorderneuronal lossrare diseasevacuoles

Identifiers

PMID40898647
PMCPMC12547491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.